| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-06-13 | Neovacs (France) | €7.6 million | The capital increase took place via a private placing, | The shares were placed with 37 investors. | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Capital increase |
| 2011-06-13 | Haemostatix (UK) | £250,000 (€284,000) | financing round | Esperante Ventures (UK) | Technology - Services - Hemostasis | Fundraising |
| 2011-06-13 | BliNK Therapeutics (UK) | up to £1.1m as seed financing, the investment to start-up the company, and up to £6.6m in further financing | seed financing | Cancer Research Technology (UK) - Kurma Life Sciences Partners (France) | Fundraising | |
| 2011-06-09 | Neovacs (France) | €1,448 million | OSEO (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Grant | |
| 2011-06-01 | Bioinvent International (Sweden) | SEK 136 million (€15.16 million) | private placement | Cancer - Oncology | Private placement | |
| 2011-06-01 | Swedish Orphan Biovitrum - SOBI (Sweden) | SEK 637 million (€71 million) | rights issue | Rare diseases - Genetic diseases | Private placement | |
| 2011-06-01 | Shield Therapeutics (UK) | €8.2 million | series A financing round | Inventages Venture Capital (UK-Switzerland-New Zealand-Bahamas) | Fundraising | |
| 2011-05-31 | Tigenix (Belgium) | € 15.2 million | capital increase | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Capital increase | |
| 2011-05-30 | Clavis Pharma (Norway) | NOK 14 million (€ 1.8 million) | grant | The Research Council of Norway | Cancer - Oncology | Grant |
| 2011-05-27 | Synairgen (UK) | £2.65 million (€3 million) | private placement | Allergic diseases - Inflammatory diseases - Respiratory diseases | Private placement | |
| 2011-05-24 | Genkyotex (Switzerland) | CHF 18 million (€14.5 million) | series C financing round | Edmond de Rothschild Investment Partners (EdRIP) (France) - Vesalius Biocapital Partners (Luxembourg) - MP Healthcare Venture Management (USA) - Eclosion (Switzerland) - SEFTI SGAM (France) - Fondation d’Aide aux Entreprises (FAE) | Cardiovascular diseases - Metabolic diseases - Respiratory diseases - Inflammatory diseases - Autoimmune diseases | Fundraising |
| 2011-05-20 | ACS Biomarker (The Netherlands) | undisclosed | financing round | Life Sciences Fund Amsterdam (The Netherlands) Limburg Ventures (The Netherlands) |
Cardiovascular diseases | Fundraising |
| 2011-05-19 | Q Chip (UK) | $6 million (£3.6 million - €4.2 million) | Series C financing round | Limburg Ventures (The Netherlands) - Nedermaas Hightech Ventures (The Netherlands) - Disruptive Capital Finance (UK) - Finance Wales UK) - an “Angel” syndicate of highly experienced individual investors including Q Chip’s Executive Chairman and biotech entrepreneur Ken Powell, British venture capitalist Jon Moulton and industrial entrepreneur Sir Harry Solomon | Cancer - Oncology | Fundraising |
| 2011-05-18 | Themis Bioscience (Austria) | €5 million | series A financing round | Crédit Agricole Private Equity (France) - Ventech (France) | Infectious diseases | Fundraising |
| 2011-05-17 | Curetis (Germany) | € 24.5 million | series A venture equity investment round | aeris Capital - LSP Life Sciences Partners (The Netherlands) - BioMedInvest (Switzerland) - KfW (Germany) - CD-Venture (Germany) - Private investors | Technology - Services - Infectious diseases | Fundraising |
| 2011-05-13 | Advicenne Pharma (France) | €5.1 million | venture capital | Innobio (France) - IXO Private Equity (France) - Private investors | CNS diseases - Renal diseases | Fundraising |
| 2011-05-12 | Midatech (UK) | £6.3 Million (€7.6 million) | private investment round | Cancer - Oncology | Fundraising | |
| 2011-05-11 | Axelar (Sweden) | SEK 123 milion (€ 13.7 million) | financing round | syndicate of investors including Karolinska Development (Sweden) | Cancer - Oncology | Fundraising |
| 2011-05-10 | Stermergie Biotechnology (Switzerland) | CHF 1.8 million (€1.3 million) | private investors | Cancer - Oncology | Fundraising | |
| 2011-05-06 | Opsona Therapeutics (Ireland) | €5.9 million | grant | European Commission’s Seventh Framework Program (FP7) | Transplantation | Grant |
